Statistics – Methodology
Scientific paper
2010-11-30
Statistical Science 2010, Vol. 25, No. 2, 217-226
Statistics
Methodology
Published in at http://dx.doi.org/10.1214/10-STS333 the Statistical Science (http://www.imstat.org/sts/) by the Institute of M
Scientific paper
10.1214/10-STS333
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major endpoint in phase II and III trials is treatment efficacy. The dose sought is typically referred to as the maximum tolerated dose (MTD). Several statistical methodologies have been proposed to select the MTD in cancer phase I trials. In this manuscript, we focus on a Bayesian adaptive design, known as escalation with overdose control (EWOC). Several aspects of this design are discussed, including large sample properties of the sequence of doses selected in the trial, choice of prior distributions, and use of covariates. The methodology is exemplified with real-life examples of cancer phase I trials. In particular, we show in the recently completed ABR-217620 (naptumomab estafenatox) trial that omitting an important predictor of toxicity when dose assignments to cancer patients are determined results in a high percent of patients experiencing severe side effects and a significant proportion treated at sub-optimal doses.
Rogatko Andre
Tighiouart Mourad
No associations
LandOfFree
Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials does not yet have a rating. At this time, there are no reviews or comments for this scientific paper.
If you have personal experience with Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials will most certainly appreciate the feedback.
Profile ID: LFWR-SCP-O-444870